Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

COVID-19 from the Perspective of Intellectual Property

Speaker(s)

Pereira da Veiga CR1, Da Veiga C2, Arcaro R1
1Universidade Federal do Paraná, Curitiba, PR, Brazil, 2Universidade Federal do Paraná, Curitiba , PR, Brazil

Presentation Documents

Objective: Patents quantify the inventive step, technical collaboration, advancement, and technological trend in a given scientific field. This work had the objective of evaluating the invention patents families related to COVID-19.

Method: This is a descriptive and documentary research of invention patents families. The patents families were selected using the keyword COVID in the title, abstract, description, the object of the invention, and concepts of the patent documents. The primary data were analyzed using the Orbit Intelligence® 1.9.8 software.

Results: This work selected 11,779 patent families from 2001 to 2021, 98% with first application year from 2020. The protection was mainly guaranteed by the World Intellectual Property Organization (3,875), European Patent Office (2,749), China (3,112), and United States of America (2,205). Among the 30 active assignees with the highest level of inventiveness, 57% were universities. Among the 11,779 patent families selected, the main International Patent Classification (IPC) Code was A61P-031, referring to patents for the invention of antiinfectives. The top applicant's main technological areas based on IPC code groupings were Pharmaceuticals and Medical Technologies. The main concepts used in the documents were related to the virus and the natural history of the disease. No strong interactions were identified in the citations between applicants in the selected patent families, except among some research institutes in China, which suggests that there is still no publication of a pioneering portfolio or blocking patents. Despite the limitation of the analysis, collaborative relationships between the different actors were also not identified.

Conclusion: Evaluating invention patents related to COVID-19 demonstrates a broad geographic and technological scope with a high degree of inventiveness based on basic science. Science could evolve more rapidly and disruptively by intensifying scientific and technological collaborations between universities, research institutes, and the pharmaceutical industries.

Code

HTA56

Disease

Infectious Disease (non-vaccine)